Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Laurent Riou
The basic science session “Imaging meets biology” provided an update on the use of the main imaging modalities that have clinical potential for the detection of vulnerable atherosclerotic plaques.
Professor Moritz Wildgruber (Munich, DE) reviewed the principles, advantages and drawbacks of molecular imaging modalities with special emphasis on the potential of invasive photoacoustic imaging for the detection of vulnerable lesions.
Professor Emmanouil Vavunarakis (Anoixi, GR) gave an excellent overview of the current knowledge regarding vasa vasorum in the setting of atherogenesis and underlined the deleterious consequences of vasa vasorum angiogenesis on plaque stability due to increased neovessel density, neovessel immaturity, and intraplaque hemorrage. He described the mechanisms and potential of contrast-enhanced ultrasound imaging for the assessment of atherosclerotic plaque neovascularisation. He stressed that several studies aimed at evaluating CEUS for vasa vasorum imaging of carotid atherosclerotic lesions have not objectively quantified the amount of lesional vasa vasorum, thereby limiting the conclusions that could be drawn.Nonlinear (harmonic response) imaging potential was also mentioned by Professor Vavuranakis through the presentation of clinical data obtained from stable and unstable carotid plaques and indicating the need for caution when interpreting CEUS images for the determination of plaque vulnerability. Finally, he reviewed the potential of nonlinear and differential IVUS imaging of coronary lesions and pointed out that IVUS detection of coronary lesions was less technically advanced than the CEUS examination of carotid arteries. He noted that molecular CEUS imaging should play a great role in the future.
Professor Olivier Gaemperli (Zurich, CH) discussed the role of inflammation in the development of vulnerable plaques and the potential molecular targets for the molecular imaging of plaque inflammation with special emphasis on SPECT/CT and TEP/CT. He reviewed the existing knowledge related to the use of FDG for PET imaging of carotid and coronary lesions and pointed the limitations of the tracer. The results recently obtained in patients with the macrophage tracer 11C-PK11195, as well as with the active calcification tracer 18F-NaF were then reviewed and the potential of molecular CT and spectral CT imaging was described.
The session ended with the talk of Professor Jean-Etienne Fabre (Strasbourg, FR) describing the use of MRI for the detection of activated platelets in vulnerable lesions. After reminding the audience of the basic physical principles underlying the use of MRI and the rational for targeting activated platelets for the imaging of vulnerable lesions, Prof. Fabre presented the data from preclinical studies evaluating the activated platelet – specific P975 and LIBS-MPIO agents using classical model of thrombosis. Very interestingly, he then presented experimental data acquired on an experimental model of mild, non occlusive thrombosis, and demonstrated that non invasive MRI using the LIBS-MPIO agent was able to detect sub-occlusive thrombosis providing that thrombus size was >2% of vessel lumen. Importantly, the feasibility of human vessel imaging was demonstrated by ex vivo MRI imaging of micro thrombi lying at the surface of an unstable, human carotid plaque.
Imaging meets biology: new strategies to identify high risk patients
© 2017 European Society of Cardiology. All rights reserved